Skip to main content

Advertisement

SpringerLink
Log in

Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

Contrast-induced nephropathy (CIN) is the major complication related to contrast media administration in patients after coronary angiography (CAG). However, inconsistent results have been published in the literature regarding the effects of pharmacological drugs on CIN prevention. We conducted a network meta-analysis to evaluate the relative efficacy of pharmacological interventions for the prevention of CIN.

Methods

We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception to July 2017. We included any randomized controlled trials of eleven pharmacological interventions that reported the prevention of CIN.

Results

We identified 3850 records through database searches, of which 107 studies comprising 21,450 participants were finally identified. Compared with intravenous saline, intravenous saline plus pharmacological drugs including statin [relative risk (RR) 0.57; 95% credibility interval (CrI) 0.39 to 0.83], N-acetylcysteine (NAC) (RR 0.84; 95% CrI, 0.71 to 0.98), vitamin and its analogues (RR 0.66; 95% CrI 0.45 to 0.97), brain natriuretic peptide (BNP) and its analogues (RR 0.46; 95% CrI 0.30 to 0.70), prostaglandin analogues (RR 0.37; 95% CrI 0.18 to 0.76), NAC plus sodium bicarbonate (SB) (RR 0.60; 95% CrI 0.39 to 0.90), and statin plus NAC (RR 0.39; 95% CrI 0.21 to 0.70), have helped to reduce the incidence of CIN in patients after CAG. The top four ranked treatments were statin plus NAC, BNP and its analogues, statin, and vitamin and its analogues, respectively. NAC plus intravenous saline was associated with lower incidence of short-term all-cause mortality than intravenous saline alone (RR 0.62; 95% CI, 0.40 to 0.96; P = 0.03). However, no evidence indicated that any of the pharmacological drugs were associated with a reduced requirement for dialysis and major adverse cardiac and cerebrovascular events (MACCE).

Conclusions

Statin plus NAC plus intravenous saline seems to be the most effective treatment for the prevention of CIN in patients after CAG. NAC plus intravenous saline may have a protective role against short-term all-cause mortality. However, none of these drugs has effectively decreased the requirement for dialysis and MACCE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mehran R (2007) Contrast-induced nephropathy remains a serious complication of PCI. J Interv Cardiol 20(3):236–240

    Article  PubMed  Google Scholar 

  2. McCullough P (2006) Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv 67(3):335–343

    Article  PubMed  Google Scholar 

  3. Rear R, Bell RM, Hausenloy DJ (2016) Contrast-induced nephropathy following angiography and cardiac interventions. Heart 102(8):638–648

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Laville M, Juillard L (2010) Contrast-induced acute kidney injury: how should at-risk patients be identified and managed? J Nephrol 23(4):387–398

    PubMed  Google Scholar 

  5. McCullough PA (2008) Contrast-induced acute kidney injury. J Am Coll Cardiol 51(15):1419–1428

    Article  PubMed  Google Scholar 

  6. Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, Shunk KA, McCullough PA, Fine MJ, Mor MK, Lew RA, Huang GD, Conner TA, Brophy MT, Lee J, Soliva S, Palevsky PM (2013) Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol 8(9):1618–1631

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mehran R, Nikolsky E (2006) Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 100:S11–S15

    Article  CAS  Google Scholar 

  8. Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Genereux P, Nikolsky E, Brener SJ, Witzenbichler B, Guagliumi G, Clark AE, Fahy M, Xu K, Brodie BR, Stone GW (2014) Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J 35(23):1533–1540

    Article  PubMed  CAS  Google Scholar 

  9. Ozcan OU, Er HA, Gulec S, Ustun EE, Gerede DM, Goksuluk H, KayaCetinErol CT (2015) Impact of metabolic syndrome on development of contrast-induced nephropathy after elective percutaneous coronary intervention among nondiabetic patients. Clin Cardiol 38(3):150–156

    Article  PubMed  Google Scholar 

  10. Heyman SN, Rosen S, Rosenberger C (2008) Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol 3(1):288–296

    Article  PubMed  Google Scholar 

  11. Ortega LM, Harmouch I, Nayer A (2015) Contrast-induced nephropathy: pathogenesis and new therapeutic options for prevention. Am J Ther 22(6):469–476

    Article  PubMed  Google Scholar 

  12. Wong PC, Li Z, Guo J, Zhang A (2012) Pathophysiology of contrast-induced nephropathy. Int J Cardiol 158(2):186–192

    Article  PubMed  Google Scholar 

  13. Mautone A, Brown JR (2010) Contrast-induced nephropathy in patients undergoing elective and urgent procedures. J Interv Cardiol 23(1):78–85

    Article  PubMed  Google Scholar 

  14. Ludwig U, Keller F (2014) Prophylaxis of contrast-induced nephrotoxicity. Biomed Res Int 2014:308316

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Solomon R, Deray G, Consensus Panel for CIN (2006) How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl 100:S51–S53

    Article  Google Scholar 

  16. Stacul F, van der Molen AJ, Reimer P, Webb JAW, Thomsen HS, Morcos SK, Almén T, Aspelin P, Bellin M-F, Clement O (2011) Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol 21:2527–2541

    Article  PubMed  Google Scholar 

  17. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, Tolwani AJ, Waikar SS, Weisbord SD (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61(5):649–672

    Article  PubMed  Google Scholar 

  18. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup (2004) Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8(4):R204–R212

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31

    Article  PubMed  PubMed Central  Google Scholar 

  20. Motohiro M, Kamihata H, Tsujimoto S, Seno T, Manabe K, Isono T, Sutani Y, Yuasa F, Iwasaka T (2011) A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol 107(11):1604–1608

    Article  PubMed  CAS  Google Scholar 

  21. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D’Ambrosio A, Montinaro A, Di Sciascio G (2011) Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty—contrast-induced nephropathy] trial. Am J Cardiol 108(1):1–7

    Article  PubMed  CAS  Google Scholar 

  22. Rezaei Y, Khademvatani K, Rahimi B, Khoshfetrat M, Arjmand N, Seyyed-Mohammadzad MH (2016) Short-term high-dose vitamin E to prevent contrast medium-induced acute kidney injury in patients with chronic kidney disease undergoing elective coronary angiography: a randomized placebo-controlled trial. J Am Heart Assoc 5(3):e002919

    Article  PubMed  PubMed Central  Google Scholar 

  23. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS (2009) N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J 157(3):576–583

    Article  PubMed  CAS  Google Scholar 

  24. Xu R, Tao A, Bai Y, Deng Y, Chen G (2016) Effectiveness of N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 5(9):e003968

    Article  PubMed  PubMed Central  Google Scholar 

  25. Subramaniam RM, Suarez-Cuervo C, Wilson RF, Turban S, Zhang A, Sherrod C, Aboagye J, Eng J, Choi MJ, Hutfless S, Bass EB (2016) Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med 164(6):406–416

    Article  PubMed  Google Scholar 

  26. Loomba RSSP, Aggarwal S, Arora RR (2016) Role of N-acetylcysteine to prevent contrast-Induced nephropathy: a meta-analysis. Am J Ther 23(1):e172–e183

    Article  PubMed  Google Scholar 

  27. Brown JR, Block CA, Malenka DJ, O’Connor GT, Schoolwerth AC, Thompson CA (2009) Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2(11):1116–1124

    Article  PubMed  Google Scholar 

  28. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784

    Article  PubMed  Google Scholar 

  29. Corbett MS, Higgins JP, Woolacott NF (2014) Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Res Synth Methods 5(1):79–85

    Article  PubMed  Google Scholar 

  30. Salanti G (2012) Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3(2):80–97

    Article  PubMed  Google Scholar 

  31. Smith TC, Spiegelhalter DJ, Thomas A (1995) Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 14(24):2685–2699

    Article  PubMed  CAS  Google Scholar 

  32. Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163–171

    Article  PubMed  Google Scholar 

  33. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS ONE 8(10):e76654

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Song F, Clark A, Bachmann MO, Maas J (2012) Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons. BMC Med Res Methodol 12:138

    Article  PubMed  PubMed Central  Google Scholar 

  35. Dias S, Welton NJ, Caldwellb DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29(7-8):932–944

    Article  PubMed  CAS  Google Scholar 

  36. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Morita Y, Numaguchi Y, Okumura K, Murohara T (2009) Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 53(12):1040–1046

    Article  PubMed  CAS  Google Scholar 

  37. Spargias K, Adreanides E, Demerouti E, Gkouziouta A, Manginas A, Pavlides G, Voudris V, Cokkinos DV (2009) Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 120(18):1793–1799

    Article  PubMed  CAS  Google Scholar 

  38. Amann U, Kirchberger I, Heier M, Zirngibl A, von Scheidt W, Kuch B, Peters A, Meisinger C (2014) Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry). Am J Cardiol 114(3):329–335

    Article  PubMed  CAS  Google Scholar 

  39. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, Sharma SK, Labinaz M, Gelormini JL, Barrett BJ (2009) Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 4(7):1162–1169

    Article  PubMed  PubMed Central  Google Scholar 

  40. Solomon R, Gordon P, Manoukian SV, Abbott JD, Kereiakes DJ, Jeremias A, Kim M, Dauerman HL, Investigators BT (2015) Randomized trial of bicarbonate or saline study for the prevention of contrast-induced nephropathy in patients with CKD. Clin J Am Soc Nephrol 10(9):1519–1524

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Maioli M, Toso A, Leoncini M, Micheletti C, Bellandi F (2011) Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. Circ Cardiovasc Interv 4(5):456–462

    Article  PubMed  Google Scholar 

  42. Xing K, Fu X, Wang Y, Li W, Gu X, Hao G, Miao Q, Li S, Jiang Y, Fan W, Geng W (2016) Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI. Heart Vessels 31(4):490–498

    Article  PubMed  Google Scholar 

Download references

Funding

This work was supported by National Nature Science Foundation of China (No. 81770451).

Author information

Authors and Affiliations

  1. Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, People’s Republic of China

    Wen-Qi Ma, Ying Wang, Xi-Qiong Han, Yi Zhu & Nai-Feng Liu

  2. Department of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, People’s Republic of China

    Yu Zhao

Authors
  1. Wen-Qi Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xi-Qiong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nai-Feng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nai-Feng Liu.

Ethics declarations

Conflict of interest

None.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 2423 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, WQ., Zhao, Y., Wang, Y. et al. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials. Int Urol Nephrol 50, 1085–1095 (2018). https://doi.org/10.1007/s11255-018-1814-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-018-1814-0

Keywords

Search

Navigation